These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34938086)

  • 41. Predictors of Mortality and Drug Resistance Among Carbapenem-Resistant Enterobacteriaceae-Infected Pancreatic Necrosis Patients.
    Wu D; Xiao J; Ding J; Jia Y; Guo Z; Liu H; Peng J
    Infect Dis Ther; 2021 Sep; 10(3):1665-1676. PubMed ID: 34215975
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia.
    Seo H; Lee SC; Chung H; Ra SH; Sung H; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Woo JH; Chong YP
    Int J Antimicrob Agents; 2020 Oct; 56(4):106126. PubMed ID: 32755654
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections.
    Hauck C; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Scalera NM; Doi Y; Kaye KS; Evans S; Fowler VG; Bonomo RA; van Duin D;
    Clin Microbiol Infect; 2016 Jun; 22(6):513-9. PubMed ID: 26850824
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of a Risk Prediction Model of Subsequent Bloodstream Infection After Carbapenem-Resistant Enterobacteriaceae Isolated from Perianal Swabs in Hematological Patients.
    Liu J; Zhang H; Feng D; Wang J; Wang M; Shen B; Cao Y; Zhang X; Lin Q; Zhang F; Zheng Y; Xiao Z; Zhu X; Zhang L; Wang J; Pang A; Han M; Feng S; Jiang E
    Infect Drug Resist; 2023; 16():1297-1312. PubMed ID: 36910516
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of a hospital-wide multifaceted programme for reducing carbapenem-resistant Enterobacteriaceae infections in a large teaching hospital in northern Italy.
    Viale P; Tumietto F; Giannella M; Bartoletti M; Tedeschi S; Ambretti S; Cristini F; Gibertoni C; Venturi S; Cavalli M; De Palma A; Puggioli MC; Mosci D; Callea E; Masina R; Moro ML; Lewis RE
    Clin Microbiol Infect; 2015 Mar; 21(3):242-7. PubMed ID: 25658534
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of a bedside tool to predict the probability of drug-resistant pathogens among hospitalized adult patients with gram-negative infections.
    Lodise TP; Bonine NG; Ye JM; Folse HJ; Gillard P
    BMC Infect Dis; 2019 Aug; 19(1):718. PubMed ID: 31412809
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical epidemiology of carbapenem-resistant enterobacteriaceae in community hospitals: a case-case-control study.
    Lee GC; Lawson KA; Burgess DS
    Ann Pharmacother; 2013 Sep; 47(9):1115-21. PubMed ID: 24259725
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incidence and risk factors of carbapenem-resistant
    Aleidan FAS; Alkhelaifi H; Alsenaid A; Alromaizan H; Alsalham F; Almutairi A; Alsulaiman K; Abdel Gadir AG
    Expert Rev Anti Infect Ther; 2021 Mar; 19(3):393-398. PubMed ID: 32930620
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization and Clinical Impact of Bloodstream Infection Caused by Carbapenemase-Producing Enterobacteriaceae in Seven Latin American Countries.
    Villegas MV; Pallares CJ; Escandón-Vargas K; Hernández-Gómez C; Correa A; Álvarez C; Rosso F; Matta L; Luna C; Zurita J; Mejía-Villatoro C; Rodríguez-Noriega E; Seas C; Cortesía M; Guzmán-Suárez A; Guzmán-Blanco M
    PLoS One; 2016; 11(4):e0154092. PubMed ID: 27104910
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sulfamoyl Heteroarylcarboxylic Acids as Promising Metallo-β-Lactamase Inhibitors for Controlling Bacterial Carbapenem Resistance.
    Wachino JI; Jin W; Kimura K; Kurosaki H; Sato A; Arakawa Y
    mBio; 2020 Mar; 11(2):. PubMed ID: 32184250
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin- and carbapenem-resistant Enterobacteriaceae.
    Freire MP; de Oliveira Garcia D; Cury AP; Francisco GR; Dos Santos NF; Spadão F; Bueno MFC; Camargo CH; de Paula FJ; Rossi F; Nahas WC; David-Neto E; Pierrotti LC
    Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):755-765. PubMed ID: 30680569
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epidemiology and risk factors for carbapenem-resistant Enterobacteriaceae colonisation and infections: case-controlled study from an academic medical center in a southern area of China.
    Fang L; Lu X; Xu H; Ma X; Chen Y; Liu Y; Hong G; Liang X
    Pathog Dis; 2019 Jun; 77(4):. PubMed ID: 31281931
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence and Outcomes of Carbapenem-resistant Bloodstream Infection in Children With Cancer.
    Nirmal G; Jithin TK; Gopakumar KG; Parthiban R; Nair C
    J Pediatr Hematol Oncol; 2023 Aug; 45(6):e678-e682. PubMed ID: 37146155
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Perianal swabs surveillance cultures of Carbapenem-resistant Enterobacteriaceae(CRE) can be hints for CRE bloodstream infection in patients with hematological diseases].
    Xu CH; Su Y; Lyu YX; Tian ZY; Sun FJ; Lin QS; Wang C
    Zhonghua Xue Ye Xue Za Zhi; 2018 Dec; 39(12):1021-1025. PubMed ID: 30612405
    [No Abstract]   [Full Text] [Related]  

  • 55. Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae.
    Harris PN; Yin M; Jureen R; Chew J; Ali J; Paynter S; Paterson DL; Tambyah PA
    Antimicrob Resist Infect Control; 2015; 4():14. PubMed ID: 25932324
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular Epidemiology and Risk Factors of Carbapenem-Resistant Klebsiella Pneumoniae Bloodstream Infections in Wuhan, China.
    Liu C; Liu L; Jin MM; Hu YB; Cai X; Wan L; Zhang HY; Li RY; Wu XJ
    Curr Med Sci; 2022 Feb; 42(1):68-76. PubMed ID: 34985611
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: a multicentre retrospective cohort study.
    Stewardson AJ; Allignol A; Beyersmann J; Graves N; Schumacher M; Meyer R; Tacconelli E; De Angelis G; Farina C; Pezzoli F; Bertrand X; Gbaguidi-Haore H; Edgeworth J; Tosas O; Martinez JA; Ayala-Blanco MP; Pan A; Zoncada A; Marwick CA; Nathwani D; Seifert H; Hos N; Hagel S; Pletz M; Harbarth S;
    Euro Surveill; 2016 Aug; 21(33):. PubMed ID: 27562950
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States.
    Satlin MJ; Chen L; Patel G; Gomez-Simmonds A; Weston G; Kim AC; Seo SK; Rosenthal ME; Sperber SJ; Jenkins SG; Hamula CL; Uhlemann AC; Levi MH; Fries BC; Tang YW; Juretschko S; Rojtman AD; Hong T; Mathema B; Jacobs MR; Walsh TJ; Bonomo RA; Kreiswirth BN
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167547
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk factors and epidemiologic predictors of blood stream infections with New Delhi Metallo-b-lactamase (NDM-1) producing Enterobacteriaceae.
    Snyder BM; Montague BT; Anandan S; Madabhushi AG; Pragasam AK; Verghese VP; Balaji V; Simões EAF
    Epidemiol Infect; 2019 Jan; 147():e137. PubMed ID: 30869056
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Carbapenem-resistant
    Adesanya OA; Igwe HA
    AIMS Public Health; 2020; 7(4):804-815. PubMed ID: 33294483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.